- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00042198
Treatment of Depression After Coronary Bypass Surgery
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Depression is a very common problem for people who have had CABG surgery, and recent studies have shown that it may increase the risk of additional medical problems and death during the first few years after surgery. Cognitive behavior therapy (CBT) has been shown to be efficacious for depression in otherwise healthy individuals, and supportive stress management (SSM) interventions have also been shown to improve depressive symptoms. These therapies have not, however, been tested for depression in individuals who have undergone CABG surgery.
Participants will be screened for depression within 1 year after CABG surgery. Those who have depression will return for additional testing 1 week later. Eligible participants will be randomized to receive CBT, SSM, or usual care (UC), with no restrictions on nonstudy antidepressants, for 12 weeks. Patients will be monitored for worsening depression referred for additional care if needed. Depression, anxiety, and health-related quality of life will be assessed at baseline, 12 weeks after randomization, and 6 months after surgery (2 months after termination of CBT or SSM).
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Missouri
-
St. Louis, Missouri, États-Unis, 63108
- Washington University School of Medicine
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Coronary Artery Bypass Graft (CABG) surgery (alone or combined with valvular or carotid surgery) within past 12 months
- Meets DSM-IV criteria for major or minor depressive episode
Exclusion Criteria:
- Severe cognitive impairment
- Severe psychiatric comorbidity (e.g., alcoholism or schizophrenia)
- Severely debilitating or life-threatening illness other than coronary disease
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: 1
Cognitive Behavior Therapy.
The treatment modality was individual, face-to-face therapy with an experienced cognitive therapist.
Treatment consisted of up to 12 weekly, hour-long sessions.
|
Up to 12 weekly, individual, hour-long sessions
|
Comparateur actif: 2
Supportive Stress Management.
The treatment modality was individual, face-to-face therapy with an experienced psychotherapist.
Treatment consisted of up to 12 weekly, hour-long sessions.
|
Up to 12 weekly, individual, hour-long sessions, focusing on application of relaxation and other stress management techniques to depressogenic stressors
|
Aucune intervention: 3
Usual Care, minimally enhanced.
Participants in all three arms were given information about depression.
There were no restrictions in any of the arms on usual care for depression, heart disease, or any other conditions, except that concurrent participation in nonstudy psychotherapy was not allowed.
Participants were allowed to continue or start on nonstudy antidepressants during the study, as prescribed by the participant's personal physician.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Hamilton Rating Scale for Depression (HAM-D-17)
Délai: 12 weeks post-randomization
|
The HAM-D-17 is an observer-rated measure of the severity of depression.
|
12 weeks post-randomization
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Beck Depression Inventory
Délai: 12 weeks post-randomization
|
The BDI is a self-report measure of the severity of depression.
|
12 weeks post-randomization
|
Beck Anxiety Inventory
Délai: 12 weeks post-randomization
|
The BAI is a self-report measure of the severity of anxiety symptoms.
|
12 weeks post-randomization
|
Beck Hopelessness Scale
Délai: 12 weeks post-randomization
|
The BHS is a self-report measure of hopelessness.
|
12 weeks post-randomization
|
Perceived Stress Scale
Délai: 12 weeks post-randomization
|
The PSS is a self-report measure of perceived stress
|
12 weeks post-randomization
|
SF-36
Délai: 12 weeks post-randomization
|
The Medical Outcomes Study SF-36 is a measure of health-related quality of life.
The Physical and Mental factor scores will be reported.
|
12 weeks post-randomization
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Kenneth E Freedland, Ph.D., Washington University School of Medicine
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- R01MH060735 (Subvention/contrat des NIH des États-Unis)
- DSIR AT-AS
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cognitive behavior therapy
-
VA Office of Research and DevelopmentComplétéTroubles de stress, post-traumatiqueÉtats-Unis
-
University of WashingtonNational Institute on Drug Abuse (NIDA)ComplétéTroubles liés à l'utilisation de substances | Troubles de stress post-traumatique | Sexe à risqueÉtats-Unis
-
Medical University of South CarolinaNational Institute on Deafness and Other Communication Disorders (NIDCD)Actif, ne recrute pasAccident vasculaire cérébral | Aphasie | Aphasie Non FluentÉtats-Unis
-
Columbia UniversityRésilié
-
NeuroTronik Inc.InconnueInsuffisance cardiaque | Insuffisance cardiaque aiguëParaguay
-
University of Applied Sciences and Arts of Southern...Vrije Universiteit Brussel; Universiteit Antwerpen; THIM - die internationale...ComplétéEn bonne santéSuisse
-
NeuroTronik Inc.InconnueInsuffisance cardiaque aiguëPanama
-
University of Roma La SapienzaComplétéÉchec de l'implant dentaire | Mucosite buccaleItalie
-
University of Alabama at BirminghamComplétéAccident vasculaire cérébral | Parésie du membre supérieur | AVC (Accident Cérébrovasculaire)États-Unis
-
Abbott Medical DevicesComplétéFibrillation auriculaire paroxystiqueAustralie, Allemagne, France, Italie, Le Portugal, Royaume-Uni